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of novel cancer drugs approved over the past 11 years are used with a curative
intent or provide a survival benefit in the palliative care setting. However, the
monthly cost for agents not providing these benefits was higher, indicating a dis-
connect between efficacy and cost.
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OBJECTIVES:To predict the potential cost and effects of addingmaleswith females
for HPV vaccination in Thailand. Human Papillomavirus (HPV) is the most com-
monly sexual transmitted virus in the United States. The American Academy of
Pediatrics (AAP) recommends HPV vaccination for adolescent. Many studies show
that HPV vaccination is beneficial in preventing HPV-associated diseases, such as
cervical cancers, cervical intraepithelial neoplasia (CIN), genital warts and others.
In Thailand, cervical cancer is the second most common cancer. The cost and
effects of vaccination in males is generally considered as beneficial as vaccine
coverage of females.METHODS: A basic model of HPV vaccination was developed
based on current literatures to estimate the economic and health effects of HPV-
associated diseases in both males and females in the United States comparing to
populations in Thailand. RESULTS: The baseline vaccination costs per case in USA
and Thailand are 500 USD and 265 USD (9283 baht) respectively. The QALYs gained
per case for both countries are 0.0126 in females and 0.0094 for combined males
and females. Totals for combinedmales and females vaccination is 493,153 QALYs
for USA and 13,957 QALYs for Thailand.CONCLUSIONS:Adding HPV vaccination in
adolescent males in Thailand is certainly more costly, but still beneficial. The po-
tential of health benefits depends more on the female HPV vaccination coverage,
however,males add benefits also. If the coverage rate for females is high, the health
benefits increase. Based on the total population, the benefits can be substantial.
PCN18
ECONOMIC EVALUATION OF CT COLONOGRAPHY (CTC) INTRODUCTION INTO
THE COLORECTAL CANCER SCREENING PROGRAM IN JAPAN
Hashimoto Y1, Igarashi A2, Miyake M3, Iinuma G3, Fukuda T4, Tsutani K2
1Graduate School of Parmaceutical Sceinces, The University of Tokyo, Tokyo, Japan, 2Tokyo Univ.
Faculty of Pharmacy, Tokyo, Japan, 3National Cancer Center, Tokyo, Japan, 4National Institute of
Public Health, Saitama, Japan
OBJECTIVES: To assess the cost-effectiveness of introducing CT colonography
(CTC) into the colorectal cancer (CRC) screening program in Japan. METHODS: A
Markovmodel for CRCwas constructed to estimate both the short-term (one-1year)
and the long-term (10-year, 20-year, and lifetime) impact of CTC on costs and
health outcomes using three strategies. Strategy-1was the current screening strat-
egy in Japan, which consists of fecal occult blood test (FOBT) and occult-colonos-
copy (OC). In Strategy-2 and Strategy-3, CTC was added between FOBT and OC. In
Strategy-2, those who were showed positive in FOBT were asked to take CTC (up-
take81.6%). In Strategy-3, only those who rejected OC (36.8%) were asked to take
CTC (uptake50%). ICERs for Strategy-2 and Strategy-3 against Strategy-1 were
calculated. Epidemiological data was obtained mainly from statistics published by
Japanese National Cancer Center. Annual discount rate for both costs and out-
comeswas set as 3%. One-way sensitivities analysis was performed. RESULTS: The
introduction of CTC into the CRC screening program in Japan was proposed to
improve the program effect. For the short-term impact, ICERs for additional CRC
detection were JPY 2,202,000 (1USD80JPY) in Strategy-2 and JPY672,000 in Strate-
gy-3, respectively. For the long-term impact, in the base-case analysis, ICERs for
additional colorectal cancer death avoided were JPY39,660,000 in Strategy-2 and
JPY2,465,000 in Strategy-3, respectively. ICERs for life-year gained were
JPY7,804,000 in Strategy-2 and JPY484,000 in Strategy-3, respectively. During esti-
mating the total lifetime impact, Strategy-3 was considered more cost saving than
Strategy-1. CONCLUSIONS: Although this study did not include the concept of
QALY, the results suggested that CTC may be likely to improve the CRC screening
program in Japan with reasonable costs. Early detection of CRC would improve
patients’ quality of life; moreover, in a long-term perspective, increased costs for
screening may be compensated for decreased costs when treating patients with
advanced CRC.
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OBJECTIVES: To estimate the cost- effectiveness of temsirolimus as a treatment
option in poor risk renal cell carcinoma compared with interferon- and from the
perspective of national health insurance in Taiwan.METHODS:Adecision-analytic
model was developed to estimate the cost effectiveness of temsirolimus. Cost and
the clinical effectiveness data were obtained from published literature and current
reimbursed price published by Bureau of National Health Insurance. All costs and
outcomes were discounted at an annual rate of 3%. The effect of parameter uncer-
tainty on cost-effectiveness was explored through extensive one-way and proba-
bilistic sensitivity analyses. RESULTS: Compared with interferon-a, temsirolimus
treatment resulted in an discounted incremental cost per QALY gained of NT$
4,775,609, based on an estimated mean gain of 0.24 quality- adjusted life years
(QALYs) per patient; and a cost per life-year gain of NT$ 2,512,048. Cost-effective-
ness estimates were most sensitive to changes in hazard ratios for overall survival
between temsirolimus and interferon-a.CONCLUSIONS: In comparisonwith inter-
feron-a, the ICER (NT$4,775,609) for temsirolimus as a treatment in poor risk renal
cell carcinoma, was found to be much higher than the threshold suggested by the
World Health Organization. Therefore, temsirolimus could not be regarded as a
cost-effective option from the National Health Insurance perspective.
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OBJECTIVES: The worldwide incidence of melanoma is increasing rapidly. Two
chemotherapy regimens are used for treatment of Malignant Melanoma: single
agent intravenous Dacarbazine (DTIC) and oral Temozolomide (TMZ). TMZ has
greater cost in Iran so we aimed to do an economic evaluation, to evaluate the
comparative value of treatment of two drugs.METHODS: To compare the efficacy
of these two drugs, a systematic review and meta-analysis were conducted and
published articles, comparing use of single agent Dacarbazine and Temozolomide
in treatment of Malignant Melanoma were reviewed. For this purpose, Pubmed,
Scopous, Web of Science and Cochrane Central Register of Controlled Trials were
searched and the search termswere: “Dacarbazine” and “Temozolomide” and “Ma-
lignantMelanoma”. Datawere collected from inception to 2012. “Response to treat-
ment” includes:” complete response (CR)”,” partial response (PR)” and “stable dis-
ease (SD)”was the key outcomeof interest. The direct cost (drug and administrative
procedures costs) was collected from health provider centers. RESULTS: Themeta-
analysis included 3 RCTS and involved 1314 patients with malignant melanoma.
Approximately half of them were allocated to the TMZ arm and half to the DTIC
arm. Risk differences for CR was -0.01, for PR was 0.03 and for SD was 0.01.
Average cost for one cycle of treatment with TMZ is $1957 and for DTIC is $90 in
Iran. For CR based on economic evaluation grid, TMZ treatment is dominated. The
incremental CE ratio for PR is $62,233 and ICER for SD is $186,700 respectively.
CONCLUSIONS: Considering health outcomes of CR, PR and SD, Temozolomide
treatment for melanoma is not cost effective comparing to Dacarbazine in Iran. It
should be mentioned that generic Dacarbazine is available in Iran but Temozolo-
mide is provided as branded, and availability to generic form of Temozolomide
may affect the results of this economic evaluations.
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OBJECTIVES: To compare the effectiveness and cost-effectiveness of erlotinib ver-
sus gefitinib in first-line treatment of epidermal growth factor receptor (EGFR) ac-
tivating-mutation positive (MuT) non-small cell lung cancer (NSCLC) for Hong
Kong. METHODS: An indirect treatment comparison (ITC), using the Bucher et al
methodology, and a cost-effectiveness assessment (CEA) were performed on the
basis of Asian phase-III randomized controlled trials (RCTs). In total four RCTswere
determined: one for erlotinib (OPTIMAL) and three for gefitinib (IPASS; NEGJSJ,
WJTOG). The CEA model uses a Markov approach that simulates the transition
between the health states: progression-free-survival (PFS), progression and death,
inmonthly cycles over a life-timehorizon. TheWorldHealthOrganization criterion
(incremental cost-effectiveness ratio  3 times GDP/capita; USD 102,582;
,HKD	798,078)was used to rate cost-effectiveness.RESULTS:The best fit of study
characteristics and of prognostic patient characteristics were found between the
OPTIMAL and IPASS trials. Comparing the PFS hazard ratios (HRs) of erlotinib vs.
gefitinib using only these RCTs in an ITC resulted in a statistically significant PFS
difference in favor of erlotinib (ITC HR: 0.33; 95% confidence-intervals: 0.19-0.58;
p0.0001). The CEA model obtained an additional benefit of 0.36 progression-free
life years gained and of 0.23 quality-adjusted life years gained (QALYs) by erlotinib,
whichwas accompanied by additional costs of USD 14,061 (HKD	109,395). The cost
per progression-free life year gained and per QALY gained were USD 39,431
(HKD	306,773) and USD 62,419 (HKD	485,619) comparing erlotinib vs. gefitinib,
respectively.CONCLUSIONS:The ITC of OPTIMAL and IPASS shows that erlotinib is
more efficacious when compared to gefitinib. The CEA for Hong Kong shows that
the costs per progression-free life year gained and the cost per QALY gained by
erlotinib are well within an acceptable range in relation to the survival benefit
obtained. Erlotinib is cost-effective compared to gefitinib in first-line EGFR MuT
NSCLC.
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OBJECTIVES: This study aimed to evaluate the long-term cost-effectiveness of dif-
ferent strategies for self-sampling of human papillomavirus (HPV) testing for cer-
vical cancer screening in Taiwan. METHODS: This study adopts a perspective of
Department of Health in cost-effectiveness analysis to compare a no-screening
strategy with seven different screening strategies. The target populations who
aged over 36 years old and didn’t attend to the regular cervical cancer screening
program over 6 years. The published Markov model of cervical cancer screening in
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Taiwanwas used in this study. There are three screening tools: 1) Pap smear alone;
2) HPV DNA testing followed by Pap smear triage; and 3) self-sampling for HPV
testing followed by Pap smear triage. Self-sampling for HPV testing strategy is
annual, and another strategies of screening intervals are annually, every 3 years,
and every 5 years. The model parameters are collected from the published refer-
ences and the health-related governments in Taiwan. Outcomemeasures included
life expectancy, quality-adjusted life years (QALYs), lifetime costs, and incremental
cost-effectiveness ratios (ICERs). Probabilistic sensitivity analyses (PSAs) were con-
ducted to assess parameter uncertainty. RESULTS: When three times GDP per
capita is used as the decision threshold, and all seven screening strategies were
cost-effective compared with the no-screening strategy. Compared with the pri-
mary screening strategy (an annual Pap smear), self-samplingHPV testing followed
by Pap smear triage, HPV DNA testing followed by Pap smear triage every 5 years
and every 3 years were cost-effective. CONCLUSIONS: Self-sampling for HPV testing
followed by Pap smear triage is one of the cost-effective screening strategies in Taiwan.
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OBJECTIVES:Gefitinib is an effective targeted therapy for a subset of non-small cell
lung cancer (NSCLC) patients, although its cost-effectiveness remains controver-
sial.. This study used national health insurance claims data to evaluate the cost-
effectiveness of gefinitib in patients with NSCLC in Taiwan. METHODS: Using
claims data and enrollment record from the 2002-2009 National Health Insurance
Research Database (NHIRD) in Taiwan, we identified lung cancer patients via the
ICD-9-CM codes.We then used ICD-9-CM and billing codes to identify patients who
had received chemotherapy containing plantinum-based regimens followed by
taxane-based regimens between November 1, 2004 and October 31, 2007. We de-
fined the index date as the date of 1st claim for taxane-based chemotherapy and
limited the observational period for cost and survival to 2 years after index date.We
further classified these patients into two groups: those who had subsequently
received gefitinib vs those had not. We determined survival status by using a pre-
viously developed algorithm using the enrollment file of the NHIRD and converted
direct medical costs to 2011 US dollars. We then calculated the net benefit for each
patient by applying various willingness-to-pay (WTP) values and employed the net
benefit regression approach to assess the cost-effectiveness of gefitinib. RESULTS:
We identified 2555 lung cancer; 979 (38%) had received gefitinib during our study
period. The average cost (standard deviation) were 64150(29482) USD for the ge-
fitinib users and 35925(27360) for non-users. The average survival was 487 days
(228) for the gefitinib users and 291 days (248) for non-users. Net benefit regression
suggested that gefitinib is cost-effective at WTP 53,000 USD/life-year or higher.
CONCLUSIONS: Among lung cancer patients who started with platinum-based
chemotherapy, followed by taxane-based regimen, adding gefitinib to chemother-
apy is likely to be cost-effective.
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OBJECTIVES: To evaluate the cost-utility of stage III colorectal cancer patients re-
ceiving either capecitabine-based or 5-FU/LV-based adjuvant treatments from the
societal perspective.METHODS: The data used in this research is being reported in
another study (Health Related Quality of Life, Direct and Indirect Cost Analysis of
Stage III Colorectal Cancer Patients Receiving Different Adjuvant Chemotherapy
Treatments in Taiwan). Direct and indirect costs, including productivity loss of
patients and their accompanying persons caused by receiving outpatient or inpa-
tient services, were involved in this study. Propensity score matching was used to
reduce selection bias and avoid endogenous problems between two groups of pa-
tients. The perspective adopted in this analysis was that of a society in Taiwan. All
costs were expressed in 2011 New Taiwan dollars (1 USD is about 30 NTD). Utility
value for the health states were derived by mapping the 16 dimensions of EORTC
QLQ-C30 onto the EQ-5D based on the published literature (McKenzie and van der
Pol, 2009). RESULTS: After propensity score matching, a total of 219 patients were
included in the analyses. There are 109 in the capecitabine-based treatment and
110 in the 5-FU/LV-based treatment. Over the study period of 6months, the average
cost of capecitabine-based treatment per patient was NT$220,576.3 while yielding
0.47 quality-adjusted life years (QALY). On the other hand, the average cost of
5-FU/LV-based treatment was NT$566,832.1 with 0.42 QALY. Between these two
adjuvant treatments, the capecitabine-based treatment was dominant.
CONCLUSIONS: As opposed to existing studies, cost and HRQoL data were directly
obtained from patients. Thus, based on patient-level information and the from the
societal perspective, our study showed that capecitabine-based treatment not only
saved costs but also improved quality-adjust life year compared with 5-FU/LV-
based treatment in the adjuvant treatment of stage III colorectal cancer in Taiwan.
CANCER - Patient-Reported Outcomes & Patient Preference Studies
PCN25
UTILITY OF ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS IN
THAILAND: PRELIMINARY STUDY
Tongpak P1, Thongprasert S2, Permsuwan U3
1Kasetsomboon Hospital, Kasetsomboon , Chaiyaphum , Thailand, 2Faculty of Medicine Maharaj
Nakorn Chiang Mai Hospital, Meung, Chiang Mai, Thailand, 3Faculty of Pharmacy Chiang Mai
University, Meung, Chiang Mai, Thailand
OBJECTIVES: Lung cancer is the common cause of cancer death in developing
countries. In Thailand, lung cancer, including non-small cell lung cancer (NSCLC)
ranks third of 10 leading sites of cancers. NSCLC has a poor prognosis which has an
effect on quality of life of both individual patients and their family. Understanding
the quality of life andhealth utility for lung cancer is important; however, little data
are available in Thailand. This study aimed to measure baseline health utility
among advance NSCLC patients before treated with first-line chemotherapy.
METHODS: A prospective cohort study was implemented in Maharaj Nakorn
Chiang Mai hospital which is a medical teaching hospital located in the north of
Thailand. A variety of first-line chemotherapy regimens were available for treat-
ment. In this study, we included patients aged 18 or above, diagnosed with NSCLC
with stage IIIB and IV, had performance status (ECOG) 0-1, and were scheduled to
receive first-line chemotherapy. The data were collected from January to March
2012. Utility was measured using EuroQoL Thai version. The data were collected
while patients visited outpatient oncology clinic. Descriptive statistics were used
for data analyses. RESULTS: During three months period, 24 patients were in-
cluded. Eight patients were NSCLC stage IIIB while 16 were stage IV. Mean utility
value of overall NSCLC, NSCLC stage IIIB and NSCLC stage IV at baseline before
receiving first-line chemotherapy were 0.419, 0.473 and 0.392, respectively.
CONCLUSIONS: Utility values of patients with advanced NSCLC are likely to be
downward due to the severity of disease; therefore, choosing the appropriate first-
line chemotherapy regimen might need to consider the quality of life of patients.
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OBJECTIVES: Benefits of treatment are often expressed as quality-adjusted life
years (QALYs). A QALY attempts to capture benefit in terms of both quantity of
survival and quality of life (QoL). Where appropriate data has not been captured in
a trial context, other methods need to be applied. The aim of this study was to
capture QoL data in the form of health state utilities, ranging from 0 (dead) to 1 (full
health), for outcomes associated with receiving therapy for rel/ref HL and sALCL.
These utilities could be used to support economic evaluation of future treatments.
METHODS: Health state descriptions or ‘vignettes’ were developed (with patient
and clinician input) depicting the burden associated with various stages of rel/ref
HL or sALCL, degree of disease response (complete [CR] or partial response, stable
or progressive disease), and adverse events (AE) experienced (B-symptoms, acute/
chronic graft-versus-host disease [GVHD], grade I/II or grade III peripheral sensory
neuropathy). Vignettes were then valued by 75 members of the general public in
Taiwan, Thailand, and South Korea using the time trade-off (TTO) methodology to
elicit utility values. RESULTS:Disease experience was associated with a significant
decline in QoL. Even a CR demonstrated a notable negative impact on QoL (Taiwan
0.597, Thailand 0.728, South Korea 0.827). The experience of any AE was associated
with substantial disutility, themost burdensome generally being acute GVHD (Tai-
wan 0.199, Thailand 0.124, South Korea 0.347). Additionally, progressive disease
was valued as having a very severe impact on QoL (Taiwan 0.229, Thailand 0.071,
South Korea 0.317).CONCLUSIONS: Experience of rel/ref HL and sALCL is viewed as
potentially devastating by individuals in all three countries. However, variations do
exist between regions, suggesting that individuals may approach the TTO exercise
differently. The results of this study may have important implications for the eco-
nomic evaluation of future treatments.
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OBJECTIVES: To investigate the cancer patients’ CAM disclosure to the health care
provider.METHODS: The study was designed as a questionnaire based, cross sec-
tional analysis. A prevalence based sample of 393 cancer patients admitted to the
oncology ward at Penang General Hospital was hereby selected for the study.
RESULTS: Of 393 patients, 184 (46.1%) were identified as CAM users and among
them126 (68.5%)were actively reported to use one ormore types of CAMat the time
of interview. CAMdisclosure rate was 43%, while only in 33.7% cases, patients been
asked by their doctors on the CAM use. The most common reason of CAM non-
disclosure was ‘not important for doctors to know about CAM’ 63 (34.2%). Among
other reasons were, ‘doctors never asked about CAM’ 15(8.2%), ‘doctors have little
knowledge about CAM’ 9(5.9%), ‘fear of CAMdisapproval by the doctors’ 8(4.3%) and
fear of termination of therapy by the doctors’ 6(3.3%). Among the demographic
variables patients having a history of regular health checkups before cancer diag-
nosis were tend to discuss their CAM use with the doctors (r0.16, p0.02). Per-
ceived severity of side effects due to conventional therapies was positively corre-
lated (r0.18, p0.014) with CAM disclosure. Patients who received
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